MAZE

Maze Therapeutics, Inc. (MAZE) | Rumor.io

Maze Therapeutics

MAZE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,914

Bullish sentiment (50-day avg)100%

Price to earnings ratio189.5

Market capitalization1.5B

Earnings per share-2.44

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-131.1M

Social

What share of all stock conversation is about MAZE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Mar 25

The company's Phase 2 HORIZON trial of MZE829 showed a 35.6% mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease.
Analysts are pitching tent poles over the AMKD data, yet the stock is down, with some attributing the selloff to high expectations and others to comparisons with another biotech company, VRTX.
The company's Q4 earnings results showed a 35.6% mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease, and expects to advance MZE829 into a pivotal program in patients with AMKD.

Generated by AI

Sentiment

Of the messages about MAZE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	93.24% -3.7
Bearish	—	0%	0% 0	6.76% +3.7

Sep 11

$MAZE has surged 46.47% and is advancing key trials for MZE829 (APOL1 kidney disease) and MZE782 (PKU/CKD), with analyst buy ratings and targets near $30.
The company has closed a $150M oversubscribed private placement at a premium, providing additional funding for its development pipeline.
Recent data from MZE782 has exceeded expectations, showing significant increases in urinary Phe excretion, supporting a best-in-class profile for the treatment of PKU and CKD.

Generated by AI

Topics

Of the messages about MAZE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	81.09%
Analysts	—	0%	0%	7.05%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	11.86%

Sep 11

Maze Therapeutics, Inc. (MAZE) has announced an oversubscribed $150 million private placement, attracting major healthcare investors at a premium price.
The company has reported positive Phase 1 results for MZE782, an oral SLC6A19 inhibitor with potential in PKU and CKD, with strong safety, target engagement, and pharmacodynamic effects observed.
Phase 2 studies for MZE782 are planned for 2026, and the company is advancing another asset, MZE829, into key trials for APOL1 kidney disease.

Generated by AI

Community

Of the messages about MAZE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	41.89%
Newcomers	—	100%	100%	58.11%

Sep 12

$MAZE boasts a deep moat, and the reigning king of scarce stocks returns, making it a Buy according to a recent stock recommendation.
Maze Therapeutics has a potentially best-in-class treatment for Phenylketonuria (PKU) and a first-in-class treatment for Chronic Kidney Disease (CKD), with Phase 2 trials planned for 2026.
The company has raised $150M in a private placement at $16.25 per share, supported by Frazier Life Sciences and Janus Henderson, to advance its Phase 2 trials for MZE782 in PKU and CKD, and MZE829 for APOL1-mediated kidney disease.

Generated by AI

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...

5d agofinance.yahoo.com

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage

Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.

6d agoYahoo Finance

Why is Maze Therapeutics stock climbing today?

7d agoInvesting.com

Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target

(Corrects brokerage firm in headline.) Maze Therapeutics (MAZE) has an average rating of buy and

7d agoYahoo Finance

BTIG Initiates Maze Therapeutics at Buy With $50 Price Target

Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $62.55, according to

7d agofinance.yahoo.com

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

7d agoInvestor's Business Daily

Also Discussed

Investors talking about MAZE also mention

#	Name	Attention
1	Revolution Medicines, Inc.RVMD	0.01%-0.01
2	BridgeBio Pharma Inc.BBIO	0%-0.02
3	Relay Therapeutics Inc.RLAY	0%new
4	Prime Medicine, Inc.PRME	0%-0.01
5	Janux Therapeutics, Inc.JANX	0%0
6	Spyre Therapeutics, Inc.SYRE	0%new
7	CNTA - Centessa Pharmaceuticals plc	——
8	Erasca Inc.ERAS	0%0
9	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
10	ETNB - 89bio, Inc.	——

Maze Therapeutics, Inc.

Healthcare
Biotechnology

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity. The company uses its human genetics-driven Compass platform to identify disease-linked genetic variants and translate those insights into targeted drug candidates. Its current pipeline includes oral programs aimed at genetically defined kidney disorders, reflecting a strategy centered on precision medicine and biologically validated pathways. Maze Therapeutics operates from South San Francisco, California, and is positioned within the broader biotechnology sector as a developer of novel therapies for patients with renal and metabolic conditions.

Website

Location

171 Oyster Point Blvd

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about MAZE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Mar 25

The company's Phase 2 HORIZON trial of MZE829 showed a 35.6% mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease.
Analysts are pitching tent poles over the AMKD data, yet the stock is down, with some attributing the selloff to high expectations and others to comparisons with another biotech company, VRTX.
The company's Q4 earnings results showed a 35.6% mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease, and expects to advance MZE829 into a pivotal program in patients with AMKD.

Generated by AI

Sentiment

Of the messages about MAZE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	93.24% -3.7
Bearish	—	0%	0% 0	6.76% +3.7

Sep 11

$MAZE has surged 46.47% and is advancing key trials for MZE829 (APOL1 kidney disease) and MZE782 (PKU/CKD), with analyst buy ratings and targets near $30.
The company has closed a $150M oversubscribed private placement at a premium, providing additional funding for its development pipeline.
Recent data from MZE782 has exceeded expectations, showing significant increases in urinary Phe excretion, supporting a best-in-class profile for the treatment of PKU and CKD.

Generated by AI

Topics

Of the messages about MAZE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	81.09%
Analysts	—	0%	0%	7.05%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	11.86%

Sep 11

Maze Therapeutics, Inc. (MAZE) has announced an oversubscribed $150 million private placement, attracting major healthcare investors at a premium price.
The company has reported positive Phase 1 results for MZE782, an oral SLC6A19 inhibitor with potential in PKU and CKD, with strong safety, target engagement, and pharmacodynamic effects observed.
Phase 2 studies for MZE782 are planned for 2026, and the company is advancing another asset, MZE829, into key trials for APOL1 kidney disease.

Generated by AI

Community

Of the messages about MAZE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	41.89%
Newcomers	—	100%	100%	58.11%

Sep 12

$MAZE boasts a deep moat, and the reigning king of scarce stocks returns, making it a Buy according to a recent stock recommendation.
Maze Therapeutics has a potentially best-in-class treatment for Phenylketonuria (PKU) and a first-in-class treatment for Chronic Kidney Disease (CKD), with Phase 2 trials planned for 2026.
The company has raised $150M in a private placement at $16.25 per share, supported by Frazier Life Sciences and Janus Henderson, to advance its Phase 2 trials for MZE782 in PKU and CKD, and MZE829 for APOL1-mediated kidney disease.

Generated by AI

Maze Therapeutics

Social

Mar 25

Sentiment

Sep 11

Topics

Sep 11

Community

Sep 12

News

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage

Why is Maze Therapeutics stock climbing today?

Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target

BTIG Initiates Maze Therapeutics at Buy With $50 Price Target

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Also Discussed

Maze Therapeutics, Inc.

Company Information

Location

News

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage

Why is Maze Therapeutics stock climbing today?

Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target

BTIG Initiates Maze Therapeutics at Buy With $50 Price Target

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Also Discussed

Social

Mar 25

Sentiment

Sep 11

Topics

Sep 11

Community

Sep 12